Provider Profile

Thumbnail
Saint Luke’s Care Member

Provider Profile

Timothy J Pluard, MD

Oncology / Hematology
Call to make an appointment 816-932-3300

Education

Medical School
Washington University School of Medicine, St. Louis, MO
Residency
Internal Medicine, University of Texas Southwestern Med School, Dallas, TX
Fellowship
Oncology, Dana-Farber Cancer Institute (Harvard Medical School), Boston, MA

Board Certifications

  • American Board of Internal Medicine - Subspecialty in Medical Oncology

Clinical Interests

  • breast cancer (including early-onset cases)
  • neodajuvant therapy of breast cancer
  • general oncology

Biography

I joined Saint Luke's Cancer Institute as medical director in August 2013. Previously, I was Associate Professor of Medicine and Clinical Director of Breast Oncology at Washington University/Siteman Cancer Center in St. Louis. I am interested in clinical research studies of new targeted therapies of breast cancer.  The care of women with breast cancer requires a multidisciplinary holistic approach from diagnosis through treatment, recovery, and survivorship. At Saint Luke's Cancer Institute, we have a superb team focused on the comprehensive care of women with breast cancer.

Accepted Insurances

  • Aetna Better Health/KanCare (KS Medicaid)
  • Aetna Choice POS II Aexcel Local
  • Aetna Choice POS II Local
  • Aetna Elect Choice POS
  • Aetna Federal Employees Health Benefit Plan HMO
  • Aetna First Health Network (excluding limited benefit plans)
  • Aetna HMO
  • Aetna HMO Local
  • Aetna Managed Choice POS
  • Aetna Medicare Plan (Medicare Advantage HMO, PPO)
  • Aetna Missouri Preferred
  • Aetna Open Choice PPO
  • Aetna Select HMO
  • Aetna Select Local HMO
  • Aetna Signature Administrators (ASA) HMO, POS, PPO
  • Aetna UAW Retiree Medical Benefits Trust (Medicare Advantage HMO, PPO)
  • Aetna Workers Comp
  • Aetna/Coventry Advantra Freedom Medicare Advantage PPO
  • Aetna/Coventry Advantra Freedom Plus Medicare Advantage PPO
  • Aetna/Coventry Advantra Total Care Medicare Advantage PPO
  • BCBS of Kansas (call provider)
  • BCBS of Kansas Blue Choice Preferred Care Blue PPO
  • BCBS of Kansas City Blue Select Plus (UCMO and City of KCMO)
  • BCBS of Kansas City Federal PPO
  • BCBS of Kansas City Freedom Network PPO
  • BCBS of Kansas City Freedom Network Select PPO
  • BCBS of Kansas City Preferred Care
  • BCBS of Kansas City Preferred Care Blue
  • BCBS of Kansas City Traditional
  • BCBS of Kansas Federal
  • BCBS of Kansas Traditional
  • BCBS of Michigan Medicare Advantage PPO
  • Blue KC Medicare Advantage HMO
  • Blue KC Medicare Advantage PPO
  • Century Health Solutions (PPO)
  • Cigna HMO
  • Cigna National POS Open Access
  • Cigna OAP
  • Cigna PPO
  • CompResults/CompAlliance (WC) PPO
  • Health Choice of Northwest Missouri (PPO)
  • Home State Health Plan Missouri Medicaid (Missouri practices)
  • Humana Choice PPO - Medicare Advantage
  • Humana ChoiceCare PPO
  • Humana Community HMO - Medicare Advantage
  • Humana Gold Choice Medicare Advantage PFFS
  • Humana Gold Plus HMO - Medicare Advantage
  • Humana Gold Plus HMO SNP - Medicare Advantage
  • Humana Kansas City PPOx
  • Humana National POS-Open Access Plans
  • Humana PPO
  • Humana Preferred PPO
  • Humana SmartExpress PPO
  • Humana SmartNet PPO
  • Humana SmartSuite PPO
  • HumanaOne PPO
  • Integrated Health Plan PPO
  • Kansas Medicaid
  • Medica Connect
  • Medica Select
  • Medicare
  • Missouri Care Health Plan - Missouri Medicaid (MO practices only)
  • MultiPlan/PCHS (PPO)
  • Occupational Health Management PPO (WC)
  • OHARA Managed Care (WC)
  • Private Healthcare Systems PPO
  • ProviDRs Care Network PPO (formerly WPPA)
  • Sunflower State Health Plan Kansas Medicaid (Kansas practices)
  • TRICARE WEST
  • Triwest Veterans Affairs Patient Centered Community Care
  • United Healthcare - All Savers Insurance Company POS
  • United Healthcare - Choice HMO
  • United Healthcare - Choice Plus POS
  • United Healthcare - Community Plan (KS Practices, KanCare, Kansas Medicaid)
  • United Healthcare - Community Plan (MO practices, Missouri Medicaid)
  • United Healthcare - Definity Health Reimbursement Account POS
  • United Healthcare - Definity Health Savings Account POS
  • United Healthcare - Golden Rule HMO (HMO & PPO)
  • United Healthcare - Indemnity
  • United Healthcare - Managed Indemnity
  • United Healthcare - Options PPO
  • United Healthcare - Select HMO
  • United Healthcare - Select Plus POS
  • United Healthcare - United Health One (Short Term Medical)
  • UnitedHealthcare - AARP Medicare Complete Choice PPO
  • UnitedHealthcare - AARP Medicare Complete HMO
  • UnitedHealthcare - AARP Medicare Complete PPO
  • UnitedHealthcare - Dual Complete SNP PPO
  • UnitedHealthcare - Group Medicare Advantage PPO
  • UnitedHealthcare - Medicare Complete PPO
  • UnitedHealthcare - Medicare Gold SNP PPO
  • UnitedHealthcare - Medicare Silver SNP PPO

Publications

Peer Reviewed Manuscripts
 
1. Adkins D, Brown R, Trinkaus K, Maziarz R, Leudke S, Freytes C, Needles B, Fracasso P, Pluard T, Moriconi W, Ryan T, Hoelzer K, Safdar S, Rearden T, Rodriguez G, Khoury H, Vij R, DiPersio J: Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol 17:2006-2014;1999.
 
2. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM; for the Cancer and Leukemia Group B: A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma. Oncologist. 2010 Dec 10. [Epub ahead of print]
 
3. Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, AdkinsDR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H., A phase I study of UCN-01 in combination with irinotrecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmocol 2010 Aug 8 [ Epub ahead of print]
 
4. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K.: Effect of Zoledronic Acid on disseminated tumor cells in women with locally advanced breast cancer: an open label, randomized phase 2 trial. Lancet Oncol May; 11(5):421-8.
 
5. Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO,Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov;136(2):355-63. doi: 10.1007/s10549-011-1910-7. Epub 2012 Jan 13.
 
6. Al Mushawah F, Rastelli A, Pluard T, Margenthaler JA. Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ. J Surg Res. 2012 Mar;173(1):10-5. doi: 10.1016/j.jss.2011.04.058. Epub 2011 May 23. PubMed PMID: 21696764.
 
Abstracts
 
1. O’Reilly EM, Niedzwiecki D, Hollis DR, Bekaii-Saab TS, Pluard T, Duffy A, Overcash F, Ivy SP, Goldberg RM. A pahse II trial of sunitinib in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol 26:2008 (May 20 suppl; abstr 4515). 
 
2. T. A. Samuel, C. Sessa, C. Britten, K. S. Milligan, M. M. Mita, U. Banerji, T. J. Pluard, P. Stiegler, C. Quadt, G. Shapiro; A phase I dose escalation study of AUY922, a novel HSP90 inhibitor in patients with advanced solid malignancies. J Clin Oncol 27:15s, 2009 (suppl; abstr 3532)
 
3. Tan BR, Myerson R, Linehan D, Hawkins W, Pluard T, Fournier C, James J, Strasberg S, Picus J. Adjuvant gemcitabine plus docetaxel followed by 5FU chemoradiation for patients with resected pancreaticobiliary cancers: A single-institution phase II study. ASCO 2008 GastrointestinalCancers Symposium, Abstract No. 237.
 
4. Hahn OM, Ma CX, Lin L, Sattar H, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard TJ, Watson MA, Ellis M, Conzen SD, Fleming GF: A Phase II Trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer.
SABCS, 2008 Abstract # 407
 
5. C. Sessa, S. K. Sharma, C. D. Britten, N. J. Vogelzang, K. N. Bhalla, M. M. Mita, T. J. Pluard, P. Stiegler, C. Quadt, G. I. Shapiro; A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. ; J Clin Oncol 27:15s, 2009 (suppl; abstr 3532)
 
6. Burstein HJ, Barry WT, Cirrincione C, Chew HK, Tolaney S, Lake D, Pluard T, Blackwell K, Winer EP, Hudis CA. CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study; Cancer Research 70(24) 109s
 
7. Roop R, Naughton M, Schneider J, Lammers P, Pluard T, Johnson F, Eby C, Weilbaecher K. Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients with Metastatic Breast Cancer: A Randomized Phase II Trial. ; Cancer Research 70(24) 250s 
 
8. Ellis M, Suman V, McCall L, Luo R, Brink A, Watson M, Ma C, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther M, Leitch M, Ota D, Olson J, Hunt K, Allred, C.: Z1031B Neoadjuvant Aromatase Inhibitor Trial: A Phase 2 study of Triage to Chemotherapy based on 2 to 4 week ki67 level >10% Presented at SABCS 2012
 
Invited Publications
 
1. Fine HA, Pluard TJ: Tumor angiogenesis: Biology and therapeutic implications In: Mauch P, Loeffler J, (eds.). Radiation Oncology: Theory and Practice.
 
2. Fehniger T, Welch J, Pluard T. Hematologic Malignancies: Chronic Leukemias. The Washington Manual of Oncology, 2nd edition, 319, 2008.

 

On Staff At

  • Hedrick Medical Center
  • Saint Luke's East Hospital
  • Saint Luke's Hospital of Kansas City
  • Saint Luke's North Hospital–Barry Road
  • Saint Luke's North Hospital–Smithville
  • Saint Luke's South Hospital